# US 2021/0196696 A1 · Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0196696 A1
- Document ID: US20210196696A1
- Status: Published application
- Kind: A1
- Application number: 17/105,453
- Filed: 2020-11-25
- Published: 2021-07-01
- Earliest claimed: 2013-12-06
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Emmanuelle di Tomaso; Christine Fritsch; Marie-Caroline Germa; Cristian Massacesi; Christian René Schnell; Ranjana Tavorath
- Web page: https://patentgrep.com/patent/US20210196696A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods of treating or preventing a proliferative disease in a patient in need thereof by orally administering a therapeutically effective amount of an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof for at least two five-consecutive day cycle, wherein said compound is not administered to the patient for a period of about two days to about three days between said five-consecutive day cycles; the use of said compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing a proliferative disease administered in accordance with said dosage regimen; therapeutic regimen comprising administration of said compound of formula (I) or a pharmaceutically acceptable salt thereof in accordance with said dosage regimen; and related pharmaceutical compositions and packages thereof.

## Claims

### Claim 1

A method of treating or preventing a proliferative disease in a patient in need thereof, comprising orally administering a therapeutically effective amount of the compound of formula (I)
or a pharmaceutically acceptable salt thereof to the patient in a daily dose of about 100 mg to about 450 mg for at least two five-consecutive day cycles, wherein said compound or a pharmaceutically acceptable salt thereof is not administered to the patient for a period of about 2 days to about 3 days between one five-consecutive day cycle and its subsequent five-consecutive day cycle.

### Claim 2 (depends on 1)

A method of treating ovary or head and neck cancer comprising first administering to a patient in need thereof a compound of formula (I) of claim 1 or a pharmaceutically acceptable salt thereof in amount of about 100 mg to about 450 mg daily on a continuous daily schedule via oral administration, second determining said patient has a side effect selected from neutropenia, elevated bilirubin, cardiac toxicity, unstable angina, myocardial infarction, persistent hypertension, peripheral sensory or motor neuropathy/pain, hepatic dysfunction, reduced red and/or white blood cell count, hyperglycemia, nausea, decreased appetite, diarrhea, rash and hypersensitivity, photosensitivity, asthenia/fatigue, vomiting, stomatitis, oral mucositis, pancreatitis, dysgeusia, and dyspepsia after administration of said compound of formula (I) or a pharmaceutically acceptable salt thereof to said patient, and third reducing the administration of said compound of formula (I) or a pharmaceutically acceptable salt thereof to a daily dose of about 100 mg to about 450 mg via oral administration for at least two five-consecutive day cycles via oral administration, wherein said compound or a pharmaceutically acceptable salt thereof is not administered to the patient for a period of about 2 days to about 3 days between one five-consecutive day cycle and its subsequent five-consecutive day cycle.

### Claim 3 (depends on 1)

The method of claim 1, wherein the daily dose of the compound of formula (I) or a pharmaceutically acceptable salt thereof is about 200 mg to about 400 mg.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound of formula (I) or a pharmaceutically acceptable salt is orally administered once per day (q.d.) in a daily dose of about 100 mg to about 450 mg for at least two five-consecutive day cycles.

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in two or more of said five-consecutive day cycles until the relief, reduction, or alleviation of the severity, occurrence rate, or frequency of at least one side effect in said patient.

### Claim 6 (depends on 5)

The method of claim 5, wherein the side effect is a condition selected from neutropenia, elevated bilirubin, cardiac toxicity, unstable angina, myocardial infarction, persistent hypertension, peripheral sensory or motor neuropathy/pain, hepatic dysfunction, reduced red and/or white blood cell count, hyperglycemia, nausea, decreased appetite, diarrhea, rash and hypersensitivity, photosensitivity, asthenia/fatigue, vomiting, stomatitis, oral mucositis, pancreatitis, dysgeusia, and dyspepsia.

### Claim 7 (depends on 6)

The method of claim 6 wherein the side effect is selected from rash and hyperglycemia.

### Claim 8

A method of treating ovary cancer in a patient in need thereof, comprising orally administering a therapeutically effective amount of the compound of formula (I)
or a pharmaceutically acceptable salt thereof to the patient in a daily dose of about 100 mg to about 450 mg for at least five-consecutive day cycles, wherein said compound or a pharmaceutically acceptable salt thereof is not administered to the patient for a period of about 2 days between on five-consecutive day cycle and its subsequent five-consecutive day cycle.

### Claim 9

A method of treating ovary cancer in a patient in need thereof, comprising orally administering a therapeutically effective amount of the compound of formula (I)
or a pharmaceutically acceptable salt thereof to the patient in a daily dose of about 100 mg to about 450 mg for at least five-consecutive day cycles, wherein said compound or a pharmaceutically acceptable salt thereof is not administered to the patient for a period of about 2 days between on five-consecutive day cycle and its subsequent five-consecutive day cycle.
